Manual external uterine compression for postpartum hemorrhage after vaginal delivery: a prospective cohort study Authors: Qing Guo, Jingxiao Zhang, Thomas Q Zheng, Hui Du, Ying Feng, Achou Su, Cui Ma, Weili Sun, Jingyi Zhao, Yao Dong Published: 2026 ABSTRACT AbstractBACKGROUNDPostpartum hemorrhage remains a leading cause of maternal mortality, particularly in low-resource settings where experienced birth attendants are scarce. Uterine massage and bimanual uterine compression have been incorporated into care bundles for many decades, yet their efficacy lacks robust supporting evidence. Bimanual uterine compression is invasive and painful for women without neuraxial analgesia.OBJECTIVEThis study aimed to assess whether manual external uterine compression could effectively control postpartum hemorrhage from uterine atony and placental pathologies after vaginal delivery.STUDY DESIGNIn this single-center, prospective cohort study of postpartum hemorrhage following vaginal delivery, we assessed the feasibility and efficacy of manual external uterine compression, a technique using the provider’s upper body weight to apply pressure to the entire uterus. Once bleeding ceased, compression was maintained for 5 to 10 minutes. The primary outcome was success rate, defined as complete resolution of uterine hemorrhage using abdominal pressure and uterotonics without requiring escalating interventions. Key secondary outcomes included compression duration, use of intrauterine balloon tamponade, blood transfusion, blood loss, hematocrit/hemoglobin change, and acceptability to providers and patients. Outcomes from the early study phase were compared with those from the later phase.RESULTSManual external uterine compression was performed in 100 women with postpartum hemorrhage over a 10-month period, achieving an overall success rate of 94% (94/100). In the early phase, the success rate was 87.8% (43/49), as 6 women used intrauterine balloon tamponade following compression. In the later phase, no balloon tamponade was used after application of MEUC. Total compression duration ranged from 2 to 50 minutes (median: 10 minutes). All women tolerated the procedure well. Eight women (8%) received blood transfusions, and none required surgery. One woman experienced delayed uterine bleeding at 145 minutes postpartum.CONCLUSIONManual external uterine compression may offer a less-invasive alternative to bimanual uterine compression for managing postpartum hemorrhage after vaginal delivery.Key words: manual external uterine compression, MEUC, postpartum hemorrhage, uterine compression; vaginal delivery AJOG Global Reports at a Glance Why was this study conducted? Early and effective control of uterine bleeding from all potential sources is critical in preventing maternal death and reducing complications. This study aimed to incorporate abdominal uterine compression early in the management of postpartum hemorrhage. Early and effective control of uterine bleeding from all potential sources is critical in preventing maternal death and reducing complications. This study aimed to incorporate abdominal uterine compression early in the management of postpartum hemorrhage. Key findings Manual external uterine compression effectively controlled postpartum hemorrhage from uterine atony and placental pathologies when used in conjunction with uterotonics, achieving an overall success rate of 94% over the 10-month study period. Manual external uterine compression effectively controlled postpartum hemorrhage from uterine atony and placental pathologies when used in conjunction with uterotonics, achieving an overall success rate of 94% over the 10-month study period. What does this add to what is known? Manual external uterine compression is a simple, safe, effective, and economical option for initial management of postpartum hemorrhage after vaginal delivery. Manual external uterine compression is a simple, safe, effective, and economical option for initial management of postpartum hemorrhage after vaginal delivery. Introduction Although maternal deaths related to postpartum hemorrhage (PPH) have steadily declined worldwide over the past 20 years, PPH remains a leading cause of preventable maternal mortality.1 Uterine atony is the most common cause of PPH and the focus of most innovative therapeutic strategies.2,3 However, the exact cause of PPH is often difficult to determine immediately after birth, and multiple etiologies may coexist.4 Focusing on one presumed source of bleeding may delay treatment of others, resulting in inadequate control of PPH and progression to coagulopathy. An ideal therapy for initial management of PPH should be simple, safe, effective, and economical, with the ability to control bleeding from all potential sources. This is especially important because most PPH-related deaths occur in low-resource settings and in situations with inexperienced birth attendants.1,5 Bimanual uterine compression (BMC) is considered a standard mechanical intervention for PPH.6, 7, 8 Although it is a century-old maneuver, BMC is invasive and can be very painful for women without neuraxial analgesia.9 Furthermore, its efficacy for controlling PPH lacks robust support from clinical trials.9,10 For the technique to be effective, sufficient pressure must be maintained for 5 to 10 minutes or longer. However, the simulation study showed that a single provider was unable to fully compress the uterus with BMC and sustain adequate compression beyond 150 seconds due to fatigue.11 To address these limitations of BMC, our institution has explored alternative approaches. For over a decade, we have used 2-person uterine compression for PPH, in which 1 person inserts a hand into the vaginal fornix while another applies abdominal pressure toward the vaginal hand, a technique described by Andreatta and colleagues.11 Since June 2025, we have tested a new method, manual external uterine compression (MEUC). This approach was initially evaluated in a feasibility study of 10 patients for rapid control of PPH due to uterine atony and placental pathology.12 The technique has been continuously refined based on staff feedback. MEUC differs from BMC in several key respects: (1) MEUC does not require placement of a hand or fist in the vagina; (2) both open hands are placed on the lower abdomen over the entire uterus; and (3) MEUC can generate higher pressure and be sustained for a longer duration than BMC. The current study aimed to assess whether manual external uterine compression could effectively control postpartum hemorrhage from uterine atony and placental pathologies after vaginal delivery. In addition, we evaluated the compression pressure and applied weight in a simulation study comparing BMC and MEUC. Material and methods Study design and setting This was a single-center, prospective cohort study conducted in the labor and delivery unit of a large specialty hospital between June 2025 and April 2026. Approximately 10,000 to 12,000 infants are born vaginally each year at this labor and delivery unit, and there are more than 100 obstetricians and nurse midwives performing vaginal deliveries. Before enrollment, the study was approved by the hospital research ethics committee (reference number 20250017). Participants All women who developed PPH immediately after vaginal delivery were eligible for the study. Informed consent was obtained from all participants. At the first sign of abnormal uterine bleeding and upon administration of uterotonics, women were briefly informed about the MEUC study and provided verbal consent. The full written consent form was then signed once the PPH was stabilized. This consent process for obstetric emergencies aligns with previous research.9,13 The inclusion criteria for initiating MEUC were: (1) bleeding from uterine cavity judged by the birth attendant to be excessive or abnormal, that is, heavy vaginal bleeding, constant trickling, or large blood clots expelled; (2) bleeding from multiple sources with uterine bleeding as one of the main causes; (3) blood loss ≥400 mL (the alert threshold recommended in China); (4) gestational age ≥24 weeks; (5) willing to participate in the study. Women with high body mass index (BMI), uterine fibroids, uterine malformations, abnormal placentation, fever, or chorioamnionitis were eligible for participation. Exclusion criteria included: (1) bleeding not from uterine cavity, that is, uterine rupture; (2) unable to apply uterine pressure from abdomen, that is, uterine inversion; (3) presence of an adnexal mass or cyst at risk of rupture; (4) severely elevated blood pressure (≥160/110 mmHg); (5) any condition in which increased abdominal pressure was contraindicated; (6) MEUC only used as a prophylactic measure in a woman at high risk for PPH. Prevention and initial management of PPH Active management of the third stage of labor is standard practice at our institution. Following fetal delivery, oxytocin 10 U in 100 mL of normal saline is routinely administered intravenously over 30 minutes, followed by a maintenance infusion of oxytocin 10 U in 500 mL of normal saline at a lower rate. Before placental delivery, a calibrated plastic drape is placed under the patient's buttocks to collect blood; fluid collected in this drape is considered exclusively blood. Additionally, all blood-soaked or stained materials are weighed. Total quantitative blood loss (QBL) is calculated by summing the volume collected in the calibrated drape and the blood volume derived from the weight of the soaked items. When PPH occurs, uterine tone and genital tract lacerations are promptly assessed. Prolonged uterine massage is not performed at our institution. Additional uterotonics and tranexamic acid (TXA) may be administered at the attending obstetrician's discretion. The uterotonics commonly used include intravenous carbetocin 0.1 mg, intramuscular ergometrine 0.2 mg, and intramuscular carboprost 0.25 mg (which may be repeated after 15 minutes, up to a total cumulative dose of 2 mg). Carboprost suppositories administered vaginally are also available. TXA 1 g is frequently given intravenously to patients with PPH, although it is not administered routinely. Manual external uterine compression (MEUC) For women with postpartum hemorrhage immediately following vaginal delivery, the protocol for MEUC was initiated after obtaining consent for MEUC and confirming inclusion and exclusion criteria. A Foley catheter is inserted to empty the bladder. The patient is placed in a lithotomy or supine position. MEUC requires the provider to apply bimanual pressure to the entire uterus (uterine fundus, uterine body, and lower uterine segment) using the weight of their upper body (Figure 1, Supplemental Video 1). Ideally, the patient’s abdominal surface should be positioned below the level of the provider’s hips. To achieve this ergonomic alignment, the provider may stand on a step stool, kneel on the bedside, or lower the bed. Rapid control of PPH with manual external uterine compression (MEUC) In this technique, the provider places both hands over the entire uterus, spanning from the pubic symphysis to the umbilicus, and applies firm vertical pressure sufficient to stop uterine bleeding. Guo. Manual external uterine compression for postpartum hemorrhage after vaginal delivery: a prospective cohort study. Am J Obstet Gynecol 2026 The uterus is pulled upward through the abdominal wall, maintaining the uterine fundus above the level of the umbilicus and aligning the uterus along the midline. If the uterus cannot be easily palpated through the abdominal wall in patients with obesity, push the uterus up through vagina then withdraw the hand. With elbows fully extended, the provider applies vertical pressure toward the spine using 2 open hands to cover the entire uterus from the pubic symphysis to the umbilicus. Pressure should be applied with sufficient intensity to stop active uterine bleeding. Once bleeding ceases, pressure should be maintained for 5 to 10 minutes. If uterine bleeding recurs after releasing the pressure, MEUC should be resumed immediately. The total duration of MEUC should be determined individually by the provider before escalating therapy. During the application of MEUC, no concurrent abdominal procedures, such as sonography, are conducted, as these would interrupt continuous uterine compression. To allow for ongoing visual assessment of bleeding from the vaginal orifice, the vagina is not tamponaded with gauze, a hand, or any instrument. If concurrent bleeding occurs from an episiotomy or perineal laceration, a second provider applies direct manual pressure to that site without disrupting the MEUC. Repair of vaginal or perineal lacerations is generally performed after heavy uterine bleeding ceases unless it is deemed necessary by the provider. To delineate the mechanism of action of MEUC, a simulation test was conducted during the study period involving 20 volunteers recruited from the staff of the labor and delivery unit. The maximum pressure and maintainable pressure were documented for both simulated MEUC and BMC. Additionally, the applied maximum weight and maintainable weight of MEUC were recorded using a scale. The time elapsed until the participant felt fatigued, as well as participants' preference for either compression method, were also documented (Supplemental material). Study variables Demographic characteristics were retrieved from electronic medical record. The primary outcome was the success rate of the MEUC defined as complete resolution of PPH without the need for escalating interventions, which included intrauterine balloon tamponade, uterine curettage, uterine artery embolization, laparotomy, uterine compression sutures, and hysterectomy. Secondary outcomes included: compression time required for control of hemorrhage; blood loss before and during MEUC; blood loss within 2 hours of delivery; changes in hematocrit and hemoglobin levels between admission and 1 day after delivery; requirement for and volume of blood transfusions; number of uterotonics administered; rebleeding after initial resolution of PPH; acceptability to providers and patients. Prior to the initiation of the study, multiple educational seminars and training sessions were conducted to ensure the staff clearly understood each step of the procedure. To study provider’s behavior and attitude toward the MEUC and their impact on the study outcomes, this 10-month long cohort study was divided into early phase (first 5 months) and later phase (last 5 months), with a design comparable to that of Haslinger et al.13 The primary and secondary outcomes were compared between these 2 phases. Statistical methods Continuous variables following a normal distribution were presented as mean±SD and compared using independent t-tests; otherwise, median (IQR) and Mann-Whitney U test were used. Count data were represented by frequencies and percentages, with the chi-squared test or Fisher test employed to assess differences. All tests were 2-sided, with significance set at P<.05. SPSS 27.0 was used for all analyses. Results Between June, 2025, and April, 2026, there were 9344 successful vaginal deliveries in our labor and delivery unit. Of these, 100 patients who experienced PPH were enrolled in the study (Figure 2 and Table 1). During the 10-month study period, 6 women with PPH received intrauterine balloon tamponade following MEUC management. One of these cases was for delayed uterine bleeding occurring 145 minutes after vaginal delivery. The overall success rate of MEUC management, based on predefined criteria, was 94% (Table 2). Study flow diagram Guo. Manual external uterine compression for postpartum hemorrhage after vaginal delivery: a prospective cohort study. Am J Obstet Gynecol 2026 Table 1Demographics, obstetric history, and delivery characteristicsTable 1 dummy alt textCharacteristicsEntire study (n=100)Early phasea (n=49)Later phasea (n=51)P-valuebAgec30.3±4.430.7±4.629.8±4.2.355Gestational weeks at deliveryd39.6 (38.6–40.1)39.7 (38.7–40.1)39.6 (38.9–40.3).574Predelivery BMIc28.6±3.429.0±3.528.5±3.4.652Number of prior pregnanciese.199 067 (67.0%)32 (65.3%)35 (68.6%) 130 (30.0%)14 (28.6%)16 (31.4%) 23 (3.0%)3 (6.1%)0 (0.0%)Epidural analgesiae99 (99.0%)48 (98.0%)51 (100%).305Type of labore.063 Induced58 (58.0%)33 (67.3%)25 (49.0%) Augmented42 (42.0%)16 (32.7%)26 (51.0%)Type of vaginal deliverye.091 Spontaneous81 (81.0%)43 (87.8%)38 (74.5%) Forceps delivery19 (19.0%)6 (12.2%)13 (25.5%)Twin vaginal deliverye5 (5.0%)2 (4.1%)3 (5.9%).680Birth weight (grams)d3497.5 (3122.5–3775.0)3500.0 (3090.0–3825.0)3465.0 (3232.5–3722.5).730Causes of postpartum hemorrhagee.061 Uterine atony only (n%)77 (77.0%)37 (75.5%)40 (78.4%) Placental pathology only (n%)3 (3%)3 (6.1%)0 (0.0%) Uterine atony plus genital tract laceration (n%)11 (11.0%)3 (6.1%)8 (15.7%) Uterine atony plus placental pathology (n%)8 (8.0%)6 (12.2%)2 (3.9%) Uterine atony plus coagulopathy1 (1%)0 (0%)1 (2%)BMI, body mass index; IQR, interquartile range; SD, standard deviationaEarly phase of the study means women enrolled between June 16 and November 15, 2025. Later phase means women enrolled between November 16, 2025 and April 15, 2026bComparison between early phase and later phasecContinuous variables are characterized by the mean±standard deviation, with differences evaluated using the t-testdContinuous variables are characterized by the median (IQR), with differences evaluated using the Mann-Whitney U testeCount data were represented by frequencies and percentages, with the chi-squared test or Fisher test employed to assess differences.Guo. Manual external uterine compression for postpartum hemorrhage after vaginal delivery: a prospective cohort study. Am J Obstet Gynecol 2026. Demographics, obstetric history, and delivery characteristics BMI, body mass index; IQR, interquartile range; SD, standard deviation Early phase of the study means women enrolled between June 16 and November 15, 2025. Later phase means women enrolled between November 16, 2025 and April 15, 2026 Comparison between early phase and later phase Continuous variables are characterized by the mean±standard deviation, with differences evaluated using the t-test Continuous variables are characterized by the median (IQR), with differences evaluated using the Mann-Whitney U test Count data were represented by frequencies and percentages, with the chi-squared test or Fisher test employed to assess differences. Guo. Manual external uterine compression for postpartum hemorrhage after vaginal delivery: a prospective cohort study. Am J Obstet Gynecol 2026. Table 2Primary and secondary outcomes during entire study, early and later phasesTable 2 dummy alt textOutcomesEntire study (n=100)Early phasea (n=49)Later phasea (n=51)P-valuebSuccess ratec94 (94.0%)43 (87.8%)51 (100%).025Total compression time (min)d10.0 (8.0–15.0)10.0 (6.0–13.0)10.0 (10.0–15.0).058Number of repeat compressionsc7 (7%)5 (10.2%)2 (3.6%).264Blood loss before compression (ml)d230.0 (200.0–305.0)250.0 (200.0–370.0)225.0 (200.0–257.5).138Blood loss during compression (mL)d128.0 (54.5–260.0)130.0 (65.0–250.0)120.0 (52.0–260.0).709Blood loss within 2-h postpartum (mL)d.251 Median (IQR)481.0 (361.5–704.5)483.0 (385.0–746.0)445.0 (359.5–657.5) Mean±SD569.5±260.0617.9±315.4523.0±189.5Hematocrit changes before and after delivery (%)e−6.1±3.9 (n=92)f−6.0±3.9 (n=43)f−6.3±4.0 (n=49)f.711Hemoglobin changes before and after delivery (g/L)e−20.7±13.3 (n=92)f−20.0±13.3 (n=43)f−21.4±13.4 (n=49)f.619Number of uterotonics usedc,g3 (2–4)3 (2–4)3 (3–4).225Tranexamic acid usedc46 (46.0%)22 (44.9%)24 (47.1%).828Number of women who received PRBCc8 (8%)6 (12.2%)2 (3.9%).156Units of PRBC transfusedc28208.135Number of Intrauterine tamponade balloon usedc660.012IQR, interquartile range; PRBC, packed red blood cells; SD, standard deviationaEarly phase of the study means women enrolled between June 16 and November 15, 2025. Later phase means women enrolled between November 16, 2025 and April 15, 2026bComparison between early phase and later phasecCount data were represented by frequencies and percentages, with the chi-squared test or Fisher test employed to assess differencesdContinuous variables are characterized by the median (IQR), with differences evaluated using the Mann-Whitney U testeContinuous variables are characterized by the mean±standard deviation, with differences evaluated using the t-testfAntepartum hematocrit and hemoglobin were measured at admission before delivery. Postpartum hematocrit and hemoglobin were measured on day 1 (approximately 24 hours) after delivery. Eight women with postpartum blood transfusions were excluded from entire study, 6 women in the early phase, and 2 women in the later phasegUterotonics included oxytocin, ergometrine, intramuscular carboprost, carboprost suppository, and carbetocin.Guo. Manual external uterine compression for postpartum hemorrhage after vaginal delivery: a prospective cohort study. Am J Obstet Gynecol 2026. Primary and secondary outcomes during entire study, early and later phases IQR, interquartile range; PRBC, packed red blood cells; SD, standard deviation Early phase of the study means women enrolled between June 16 and November 15, 2025. Later phase means women enrolled between November 16, 2025 and April 15, 2026 Comparison between early phase and later phase Count data were represented by frequencies and percentages, with the chi-squared test or Fisher test employed to assess differences Continuous variables are characterized by the median (IQR), with differences evaluated using the Mann-Whitney U test Continuous variables are characterized by the mean±standard deviation, with differences evaluated using the t-test Antepartum hematocrit and hemoglobin were measured at admission before delivery. Postpartum hematocrit and hemoglobin were measured on day 1 (approximately 24 hours) after delivery. Eight women with postpartum blood transfusions were excluded from entire study, 6 women in the early phase, and 2 women in the later phase Uterotonics included oxytocin, ergometrine, intramuscular carboprost, carboprost suppository, and carbetocin. Guo. Manual external uterine compression for postpartum hemorrhage after vaginal delivery: a prospective cohort study. Am J Obstet Gynecol 2026. All cases requiring intrauterine balloon tamponade occurred in the first 5 months of the study. During this early phase, the success rate of MEUC management was 87.8% (43/49). In the latter phase, no intrauterine balloon tamponade was used after application of MEUC. Among the 5 women with unsatisfactory results from MEUC management who subsequently received intrauterine balloon tamponade during the early phase, the duration of MEUC management (mean 7.20 minutes; median 6 minutes) was shorter than that in women with satisfactory outcomes (mean 13.30 minutes; median 10 minutes). This difference did not reach statistical significance (P=.176, nonparametric tests). The total duration of MEUC ranged from 2 to 50 minutes, with a median of 10 minutes. All women tolerated the procedure well, and none refused continuation due to pain or discomfort. No adverse events were directly attributable to the procedure. All women were followed for at least 2 weeks after discharge, with no reported cases of recurrent uterine hemorrhage or readmission. All enrolled women received uterotonic therapy, ranging from 1 to 4 agents (median 3), and oxytocin was the only uterotonic agent given to all women after vaginal delivery. About 46 women (46%) were administered 1 g of tranexamic acid. No women with PPH required invasive interventions such as uterine curettage, uterine artery embolization, or laparotomy. Eight women (8%) received transfusions of 2 to 4 units of packed red blood cells (PRBC): 6 in the early phase and 2 in the later phase. Of note, in China, 1 unit of PRBC is derived from 200 mL of whole blood. The difference in blood product transfusion (units or volume) between the early and later phases was not statistically significant. MEUC was applied to women with uterine bleeding from various etiologies, with similarly satisfactory results. Primary and secondary outcomes were compared between the early and later phases of the study (Table 2). Only the number of intrauterine balloon tamponade uses, 6 in the early phase vs zero in the later phase, reached statistical significance (P=.01). While the technique for manual external uterine compression remained unchanged throughout the 10-month study period, we observed a notable increase in staff confidence over time. Clinicians tended to apply compression for longer duration and were less inclined to escalate to more invasive interventions prematurely. Among the 9344 successful vaginal deliveries during the 10-month study period, a total of 12 women (0.13%) required transfusion of blood products. Of these, 8 were enrolled in our study, and 4 were outside the study. No women required surgical interventions for PPH after vaginal delivery (eg, laparotomy or uterine artery embolization). There were no maternal deaths or cases of organ failure. In simulated BMC, participants at maximum effort were able to compressed a mean pressure of 37.9 mmHg, but felt tired after compressing a mean of 104 seconds. During the 5-minute compression with simulated BMC, participants were able to maintain a mean pressure of 19.6 mmHg. In simulated MEUC, participants compressed a mean of 142.6 mmHg and 7.2 kg at maximum effort and 116.3 mmHg and 6.2 kg at maintainable effort while not feeling tired most times. Participants unanimously preferred MEUC over BMC (Supplemental material). Discussion Principal findings In this prospective cohort study, we found that MEUC was feasible in patients with PPH and effectively arrested uterine bleeding when used in conjunction with uterotonics and other standard therapies. MEUC could be sustained as long as needed to control intrauterine hemorrhage resulting from various etiologies, including uterine atony and placental pathologies, achieving an overall success rate of 94% over the 10-month study period. Results in context During the early phase of the study, adherence to the MEUC protocol was inconsistent, characterized by premature cessation of compression or premature escalation to intrauterine balloon tamponade despite clinical improvement. This tendency likely stemmed from greater familiarity with intrauterine balloons. Per study protocol, any such escalation was classified as a treatment failure of MEUC, resulting in an initial success rate of 87.8% (43 of 49 patients) during the first 5 months of the study. As clinical experience grew, provider proficiency and confidence in the MEUC technique improved significantly. In the later phase of the study (subsequent 51 patients), the requirement for Bakri balloons was eliminated. Compared to the early phase of the study, reduction of blood transfusion was observed in the later phase of the study, but not statistically significant. At our institution, we do not include prolonged uterine massage in first-line treatment for PPH, because the quality of evidence supporting its use in this context is low.14 To date, no randomized trial has evaluated uterine massage specifically for the treatment of PPH. The World Health Organization (WHO) has included uterine massage in first-line PPH treatment largely due to its benign nature, low resource requirements, and global feasibility.14 In contrast, strong evidence indicates that uterine massage before or after placental delivery is ineffective for PPH prevention.15, 16, 17 Consistent with this, the WHO recommends against sustained uterine massage as an intervention to prevent PPH in women who have received prophylactic oxytocin.14,18 Rapid and early control of uterine bleeding has been the top priority in PPH management at our labor and delivery unit. Two-person uterine compression and now MEUC are integral components of our management strategy. With this approach, the incidence of severe PPH requiring invasive procedures in our labor and delivery unit has remained low. Among 9344 vaginal deliveries during the 10-month study period, there were no maternal deaths, no cases of organ failure, and no need for surgical interventions (eg, laparotomy or uterine artery embolization) that are related to PPH. Clinical implications When applying MEUC, we do not recommend performing abdominal ultrasound, intrauterine exploration, or cervical examination and suturing unless absolutely indicated, as these interventions can interrupt uterine compression and divert staff attention. Once uterine bleeding is arrested, a thorough examination of the genital tract can be performed, and lacerations can be repaired as needed. By avoiding insertion of a hand into the vagina, MEUC improves patient comfort and tolerance. With the vaginal opening unobstructed, the entire team can easily assess the efficacy of uterine compression throughout the procedure. We recommend that delivery units consider incorporating MEUC training into PPH protocols, particularly before escalating to other invasive therapy. Our simulation study demonstrated that standard bimanual uterine compression (BMC) was unable to deliver sufficiently high pressure for a prolonged period to be effective. In simulated BMC, providers felt fatigued after only 104 seconds of compression by hand, and the maintainable pressure generated was below 20 mmHg (Supplemental material). These results are consistent with previous reports indicating that BMC performed by a single provider does not provide extended compression for optimal effect.11 In contrast, MEUC delivers substantially greater pressure using the provider's upper body weight and can be maintained steadily during a 5-minute compression period. Aortic compression remains a temporary, life-saving measure in desperate situations.19 In the most recent report on the use of the Abdominal Aortic and Junctional Tourniquet—Stabilized (AAJT-S) to control PPH, 3 of 4 patients (75%) resumed bleeding upon release of aortic compression and required immediate laparotomy.20 In our cohort, MEUC was incorporated as first-line therapy for immediate PPH management, and uterine bleeding was successfully controlled in all women during the later half of the study, with no invasive procedure including intrauterine balloon tamponade required. MEUC arrests PPH by markedly decreasing blood flow to the entire uterus and promoting hemostasis of the placental bed through sustained flow reduction. Collapsing the uterine cavity may also facilitate uterine contraction.21 By rapidly controlling hemorrhage, MEUC can prevent progression to coagulopathy. In addition, it provides valuable time for uterotonics to take effect and for a multidisciplinary team to be mobilized. The mechanism by which MEUC achieves hemostasis differs fundamentally from that of aortic compression, which may require over 250 mmHg of pressure or more than 140 pounds (63 kg) of weight to occlude aortic flow.20,22,23 Achieving such forces manually is extremely difficult, whether in a simulation setting or a clinical emergency.22, 23, 24 In our simulated MEUC model using a soft delivery bed, the highest pressure and weight briefly generated by 1 female staff member with a body weight of 85 kg were only 190 mmHg and 10.2 kg, respectively. This suggests that the MEUC maneuver is unlikely to completely block abdominal aortic blood flow. However, because we did not monitor femoral arterial flow or lower extremity blood pressure during the study, whether MEUC partially compresses the aorta and reduces pelvic perfusion remains unknown. Research implications Future research should prioritize a randomized trial comparing MEUC plus standard care vs standard care alone, with stratification by BMI, parity, history of cesarean delivery, and epidural analgesia. Studies should also evaluate patient-reported outcomes including pain and satisfaction, and assess MEUC's utility in delayed PPH or out-of-hospital settings. Strengths and limitations The strengths of this study lie in the prospective design and the use of simulation to corroborate clinical findings. This study has several limitations. First, the concurrent administration of multiple uterotonics, a standard practice for PPH management at our institution, presents a significant confounding factor. Second, the lack of a control group precludes direct causal inference. Third, our cohort consisted primarily of primiparous women with low BMI at delivery (mean 28.6) who received epidural analgesia during labor. Fourth, we employed a low threshold to initiate MEUC, which may limit the generalizability of our findings and could potentially inflate the apparent success rate of the intervention. It is noteworthy, however, that the E-MOTIVE trial also used a similarly low threshold, initiating PPH treatment at blood losses as low as 300 mL.25 Moreover, the decision to use this lower threshold was influenced by the comparatively lower average BMI of 28.6 of pregnant women in our cohort vs that reported in U.S. cohorts (BMI 35.1),2 making initiation of MEUC at a higher blood loss less practical. Conclusion Early and rapid control of uterine bleeding following vaginal delivery is critically important. MEUC is a safe, effective, and well-tolerated maneuver for women with postpartum hemorrhage. It delivers substantially higher pressure to the uterus than standard bimanual compression and obviates the need to insert a hand into the vaginal fornix. Declaration of generative AI and AI-assisted technologies in the manuscript preparation process During the preparation of this work, the authors used DeepSeek to check grammar and sentence fluidity. After using this AI tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the published article. CRediT authorship contribution statement Qing Guo: Writing – review & editing, Supervision, Resources, Conceptualization. Jingxiao Zhang: Writing – review & editing, Supervision, Resources, Project administration, Conceptualization. Thomas Q. Zheng: Writing – review & editing, Writing – original draft, Visualization, Supervision, Project administration, Investigation, Formal analysis, Conceptualization. Hui Du: Resources, Project administration, Investigation. Ying Feng: Resources, Methodology, Investigation. Achou Su: Software, Formal analysis. Cui Ma: Investigation. Weili Sun: Investigation. Jingyi Zhao: Validation, Investigation, Data curation. Yao Dong: Visualization. Footnotes The authors report no conflict of interest. Funding: None. This study was approved by the Shijiazhuang Obstetrics and Gynecology Hospital Research Ethics Committee (reference number 20250017). Tweetable statement: Abdominal uterine compression is safe and effective for initial management of postpartum hemorrhage after vaginal delivery. Supplementary material associated with this article can be found in the online version at doi:10.1016/j.xagr.2026.100695. Supplementary materials Supplemental Material: Simulation test of bimanual uterine compression and manual external uterine compression Figure S1: Simulation test of bimanual uterine compression (BMC) Figure S2: Simulation test of manual external uterine compression (MEUC) Video S1 legend: Manual external uterine compression (MEUC) Length: 2 minutes Size: 80.5 MB All participants in the video have given consent for publication. Table S1: Simulation testing results of compression pressure and weight by 20 female volunteer participants Table S2: 20 female volunteer participants’ individual data of compression pressure and weight References Associated Data Supplementary Materials Supplemental Material: Simulation test of bimanual uterine compression and manual external uterine compression Figure S1: Simulation test of bimanual uterine compression (BMC) Figure S2: Simulation test of manual external uterine compression (MEUC) Video S1 legend: Manual external uterine compression (MEUC) Length: 2 minutes Size: 80.5 MB All participants in the video have given consent for publication. Table S1: Simulation testing results of compression pressure and weight by 20 female volunteer participants Table S2: 20 female volunteer participants’ individual data of compression pressure and weight